Skip to main content

Mylan gets OK for generic Femara

4/25/2011

PITTSBURGH — Mylan has launched a generic treatment for breast cancer, the drug maker said Monday.


Mylan announced the launch of letrozole tablets in the 2.5-mg strength, an adjuvant treatment for postmenopausal women with hormone receptor-positive early-stage breast cancer.


The drug is the first generic version of Novartis’ Femara, which had sales of about $682 million in 2010, according to IMS Health.

X
This ad will auto-close in 10 seconds